Table 2.

Cost, resource utilization, and market share data from nine European countries used to populate the economic model

	Austria	Belgium	Czech Republic	Hungary	Italy	Latvia	The Netherlands	Poland	Portugal
Costs (€)
Eligard® 1 M (7.5 mg)	106.80	95.70	121.60	100.39	149.77	111.66	106.80*	81.78	148.20
Eligard® 3 M (22.5 mg)	320.40	194.52	314.95	280.55	387.49	319.03	320.40	240.57	399.41
Eligard® 6 M (45 mg)	619.22	320.06	629.93**	558.11	774.98	466.87	619.22	481.14	779.66
Urologist consultation§	29.42	28.56	4.23	2.42	20.70	38.96	86.00	8.65	35.43
PSA test	11.10	10.78	14.46	4.75	19.10	7.14	27.65	7.21	8.14
Ultrasound scan	27.66	37.37	12.10	1.80	43.40	12.99	85.00	7.21	43.16
Adverse events#	21.80	18.24	4.23	1.79	20.70	16.88	86.00	3.85	35.43
Nonmedical cost per visit‡	5.70	4.40	3.57	5.22	4.00	10.39	7.00	2.16	4.20
Indirect cost per visit||	23.81	33.70	6.80	6.25	28.57	6.18	33.91	7.93	11.55
Resource utilization (%) – diagnostic visits
Monthly	0.24	0.24	0.90	0.88	0.90	0.90	0.24	0.90	0.90
3-monthly	4.75	4.75	9.00	8.77	9.00	9.00	4.75	9.00	9.00
Estimated market share (%)
Eligard® 1 M	20.0	30.0	10.4	32.0	10.0	15.0	0	2.2	8.0
Eligard® 3 M	60.0	70.0	90.6	68.0	87.0	80.0	20.2	65.8	90.0

Notes:

^*1 M formulation was not marketed and its unit cost was assumed to be one-third of the 3 M formulation;

^**monthly cost assumed to be equivalent to that of 3 M and was varied in the sensitivity analysis;

^§doctor, nurse, and injection costs;

^#GP/urologist consultation;

^‡public transport;

^||productivity loss based on minimum wage and accounting for retirement status. Registered trademarks of Eligard®, Sanofi S.A./Tolmar Therapeutics Inc (Fort Collins, CO, USA).

Abbreviations: 1 M, 1-monthly; 3 M, 3-monthly; 6 M, 6-monthly; PSA, prostate-specific antigen; GP, general practitioner.